Cargando…
Evolving Natural History of Metastatic Prostate Cancer
Introduction The systemic therapies available to patients with metastatic prostate cancer (mPC) have improved dramatically over the past decade. Anecdotal experience suggests that the increased available lines of therapy have changed the profile of mPC to include a higher prevalence of visceral meta...
Autores principales: | Nafissi, Nellie N, Kosiorek, Heidi E, Butterfield, Richard J, Moore, Cassandra, Ho, Thai, Singh, Parminder, Bryce, Alan H |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7735525/ https://www.ncbi.nlm.nih.gov/pubmed/33329980 http://dx.doi.org/10.7759/cureus.11484 |
Ejemplares similares
-
Differential impact of tumor suppressor gene (TP53, PTEN, RB1) alterations and treatment outcomes in metastatic, hormone-sensitive prostate cancer
por: Velez, Miguel Gonzalez, et al.
Publicado: (2021) -
A Case Report on Atypical Presentation of Metastatic Prostate Cancer
por: Lyonga Ngonge, Anthony, et al.
Publicado: (2022) -
Disseminated Intravascular Coagulation as the Initial Presentation of Metastatic Prostate Adenocarcinoma
por: Greenberg, Daniel J
Publicado: (2021) -
Stauffer Syndrome as the Initial Presentation of Advanced Metastatic Prostate Cancer
por: Khanal, Sneha, et al.
Publicado: (2023) -
An Insight Into the Factors Affecting the Prevalence and Natural History of Hepatitis D
por: Abbas, Zaigham, et al.
Publicado: (2023)